Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit. In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank dramatically. Moreover, the tumors showed stable disease for at least 9 months. To the best of our knowledge, it is the first report about a response of advanced thymic carcinoma to sorafenib. The preliminary study suggested that molecular target-based therapy could be an alternative treatment to those chemotherapy-refractory patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-008-9100-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IDEAL-IQ Magnetic Resonance Imaging Fat Fraction Quantification in Distinguishing Thymic Hyperplasia From Low-Risk Thymoma and Thymic Lymphoma in Adulthood: A Reliability and Efficacy Analysis.
J Comput Assist Tomogr
November 2024
From the Department of Radiology & Functional and Molecular Imaging Key Lab of Shaanxi Province.
Objectives: Detection of fat content in thymic lesions is essential to differentiate thymic hyperplasia from thymic tumors. This study assesses the reliability and efficacy of "iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantization" IDEAL-IQ magnetic resonance sequence in distinguishing thymic hyperplasia from low-risk thymoma and thymic lymphoma in adulthood.
Methods: Thirty patients with thymic hyperplasia, 28 low-risk thymomas, and 13 thymic lymphomas were respectively enrolled.
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Clin Lung Cancer
December 2024
Georgetown University, Washington, DC. Electronic address:
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.
View Article and Find Full Text PDFImmunotherapy in thymic epithelial tumors: an attractive dilemma.
Invest New Drugs
January 2025
Department of Hematology-Oncology, Faculty of Medicine, Hôtel Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.
Thymomas and thymic carcinomas are the most prevalent tumors that develop in the thymus's epithelial tissue. Thymomas are malignant tumors that develop from the epithelial cells of the thymus and frequently include mixed populations of lymphocytes. In contrast, thymic carcinomas are also tumors of the thymic epithelium, but they are characterized by a lack of lymphocytes, exhibit more aggressive behavior, and are associated with a poorer prognosis.
View Article and Find Full Text PDFType 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention.
J Clin Invest
January 2025
Department of Dermatology, and.
Article Synopsis
- The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) are increasing, highlighting the urgent need for better prevention methods.
- Topical treatments like calcipotriol and 5-fluorouracil (5-FU) can eliminate actinic keratosis (AK) lesions, but their exact mechanisms weren't clear until recent research.
- A study shows that type 2 immunity, specifically the interaction between thymic stromal lymphopoietin (TSLP) and Th2 cells, is crucial for eliminating premalignant cells and could be targeted for cSCC prevention.
T helper 2 cell-directed immunotherapy eliminates precancerous skin lesions.
J Clin Invest
January 2025
Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
The continuous rise in skin cancer incidence highlights an imperative for improved skin cancer prevention. Topical calcipotriol-plus-5-fluorouracil (calcipotriol-plus-5-FU) immunotherapy effectively eliminates precancerous skin lesions and prevents squamous cell carcinoma (SCC) in patients. However, its mechanism of action remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!